文献速递系统性红斑狼疮其他结缔组织病

系统性红斑狼疮与老年早期乳腺癌患者死亡率的关系

Systemic Lupus Erythematosus and Mortality in Elderly Patients With Early Breast Cancer.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-11-26

本研究基于德克萨斯癌症登记处和SEER数据库链接Medicare理赔数据,比较老年女性早期乳腺癌合并SLE与不合并SLE的生存率。匹配年龄和癌症分期后,合并SLE的早期乳腺癌患者8年总生存率为52%,显著低于不合并SLE者的74%;多变量Cox模型显示合并SLE增加死亡风险(HR 1.65)。

要点

  • 合并SLE的早期乳腺癌患者8年总生存率显著低于不合并SLE者(52% vs 74%)。
  • 合并SLE使早期乳腺癌患者死亡风险增加(HR 1.65,95%CI 1.38-1.98)。
  • 合并SLE的乳腺癌患者接受放疗、保乳手术和内分泌治疗的比例较低。

核心结论

  • 系统性红斑狼疮是老年女性早期乳腺癌患者死亡风险增加的独立危险因素。

研究设计与样本

  • 基于德克萨斯癌症登记处和SEER数据库链接Medicare理赔数据的回顾性队列研究,纳入494例乳腺癌合并SLE患者和145,517例乳腺癌不合并SLE患者,按年龄和癌症分期匹配后分析。

主要发现

  • 匹配后早期乳腺癌(0-II期)合并SLE与不合并SLE的8年总生存率分别为52%(95%CI 45%-59%)和74%(95%CI 73%-75%)。
  • 多变量Cox模型显示乳腺癌合并SLE的死亡风险比为1.65(95%CI 1.38-1.98)。
  • 合并SLE的乳腺癌患者相比无癌症的SLE患者死亡风险增加(HR 1.42,95%CI 1.05-1.92)。
  • 合并SLE的乳腺癌患者接受放疗、保乳手术或内分泌治疗的比例较低。
  • 合并SLE的乳腺癌患者诊断癌症后接受糖皮质激素、抗疟药和免疫抑制剂的比例低于无癌症的SLE患者。

临床怎么用

  • 对合并SLE的早期乳腺癌老年患者应加强多学科管理,关注其较低的乳腺癌治疗接受率和较高的死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with cancer and systemic lupus erythematosus (SLE) may have worse outcomes than those without SLE, given their comorbidities. We examined survival in elderly women with breast cancer (BC) and SLE and hypothesized that survival would be decreased compared with women with BC but without SLE. METHODS: We identified patients with BC and SLE and patients with BC without SLE in the Texas Cancer Registry and Surveillance, Epidemiology, and End Results, linked to Medicare claims. Overall survival (OS) was estimated after matching (age and cancer stage) and in multivariable Cox proportional hazards models adjusting for other cancer characteristics, treatment, and comorbidities. Two additional cohorts of women without cancer with and without SLE were also studied. RESULTS: We identified 494 BC SLE cases and 145,517 BC non-SLE cases, of whom we matched 9,708. Women with SLE were less likely to receive radiation, breast conserving surgery, or endocrine therapy. The 8-year OS estimate for women with early BC (stages 0-II) with and without SLE was 52% (95% confidence interval [95% CI] 45%-59%) and 74% (95% CI 73%-75%), respectively. In the Cox multivariable model, BC and SLE had increased risk of death (hazard ratio [HR] 1.65, 95% CI 1.38-1.98). Women with BC and SLE also had increased risk of death compared with women with SLE but without cancer (HR 1.42, 95% CI 1.05-1.92) after adjusting for SLE severity. Women with SLE and BC received less glucocorticoids, antimalarials, and immunosuppressants after cancer diagnosis than those without cancer. CONCLUSION: Systemic lupus is a risk factor for increased mortality in women with early BC.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Bruera S, Lei X, Pundole X, et al. Systemic Lupus Erythematosus and Mortality in Elderly Patients With Early Breast Cancer. Arthritis Care Res (Hoboken). 2022. PMID: 34558796. doi:10.1002/acr.24793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。